1
|
Ferrari AC, Stone N, Kurek R, Mulligan E, Stock R, Unger PD, Hall S, Kaisary AV, Gallagher RE, Mandeli JP. Outcome study of patient (pts) with localized prostate cancer (PC) staged by reverse transcription quantitative real-time-PCR (QRT-PCR) analysis of prostate specific antigen (PSA) mRNA levels in pathologically normal (NO) pelvic lymph nodes (PLN). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. C. Ferrari
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - N. Stone
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - R. Kurek
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - E. Mulligan
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - R. Stock
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - P. D. Unger
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - S. Hall
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - A. V. Kaisary
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - R. E. Gallagher
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| | - J. P. Mandeli
- Mount Sinai School of Medicine, New York, NY; Stadtische Klinikem, Offenbach am Main, Germany; Royal Free Hospital, London, United Kingdom; Albert Einstein College of Medicine, Bronx, NY
| |
Collapse
|
2
|
Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, Woo SL. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001; 4:182-91. [PMID: 11545608 DOI: 10.1006/mthe.2001.0444] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Animal studies have shown that direct injection of an adenoviral vector (Adv.RSV-tk) expressing the herpes thymidine kinase gene into established tumors in the liver, followed by systemic ganciclovir administration, was effective in inducing tumor necrosis. Toxicities were minimal at therapeutically effective vector doses, although severe hepatic necroinflammation was seen at much higher supratherapeutic doses. We conducted a clinical phase I trial in patients with metastatic colorectal adenocarcinoma in the liver to assess the safety of intratumoral Adv.RSV-tk injection (escalating doses) followed by intravenous ganciclovir (fixed dose). The vector was injected into a metastatic tumor in the liver under local anesthesia by percutaneous needle placement with concurrent ultrasonographic monitoring to prevent injection or leakage into adjacent normal liver structures. We treated 16 patients in five dose level cohorts of Adv.RSV-tk, from 1.0x10(10) to 1.0x10(13) virus particles per patient. Hepatic toxicities were low, with transient grade 1 elevations in serum aminotransferase levels in 3 of 16 patients. Other toxicities were also transient: grade 2-3 fevers in 5 of 16 patients, grade 3 thrombocytopenia in 1 of 16 patients, and grade 2 leucopenia in 3 of 16 patients. These results indicate that Adv.RSV-tk can be safely administered by percutaneous intratumoral injection in patients with hepatic metastases at doses up to 1.0x10(13) virus particles per patient, and can provide the basis for future clinical trials involving intratumoral adenoviral vector injection.
Collapse
Affiliation(s)
- M W Sung
- Division of Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
| | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
BACKGROUND The biologic activity of vitamin A depends, in part, on its metabolism to active nuclear receptor ligands, chiefly retinoic acid. The cellular retinol-binding protein (CRBP) binds vitamin A with high affinity and is postulated to regulate its uptake and metabolism. In this report, we analyze the expression of CRBP in normal and malignant breast tissues. METHODS We evaluated CRBP expression by in situ hybridization in six reduction mammoplasty specimens and 49 human breast carcinoma specimens by use of digoxigenin-labeled RNA probes and in nine cultured mammoplasty specimens by northern or western blot analysis. Statistical significance was evaluated with the chi(2) test or Fisher's exact test if the sample sizes were small. All P values are from two-sided tests. RESULTS CRBP was expressed in all 15 mammoplasty specimens (normal breast tissue) and in 33 of 35 available specimens of normal tissue adjacent to carcinoma. In contrast, 12 (24%) of 49 carcinoma lesions were uniformly negative for CRBP (P =.023 for comparison with adjacent normal breast tissue). The loss of CRBP expression was as frequent in ductal carcinoma in situ (six [27%] of 22) as in invasive lesions (six [22%] of 27), suggesting that it is a relatively early event in carcinogenesis and not associated with patient age, tumor grade, and expression of steroid receptors or c-Myc. Preliminary experiments did not find an association between CRBP and retinoic acid receptor beta loss, but most (four of five) CRBP-negative tumors were also retinoic acid receptor beta negative. CONCLUSION CRBP is underexpressed in 24% (95% confidence interval = 12.5%-36.5%) of human breast carcinomas, implying a link between cellular vitamin A homeostasis and breast cancer. We hypothesize that the loss of CRBP restricts the effects of endogenous vitamin A on breast epithelial cells.
Collapse
MESH Headings
- Blotting, Northern
- Breast/metabolism
- Breast Neoplasms/chemistry
- Breast Neoplasms/pathology
- Carcinoma in Situ/chemistry
- Carcinoma in Situ/pathology
- Carcinoma, Ductal, Breast/chemistry
- Carcinoma, Ductal, Breast/pathology
- DNA, Complementary
- Female
- Gene Expression Regulation, Neoplastic
- Genes, myc
- Humans
- In Situ Hybridization
- Mammaplasty
- RNA, Neoplasm/chemistry
- Receptors, Retinoic Acid/analysis
- Retinol-Binding Proteins/analysis
- Retinol-Binding Proteins/genetics
- Retinol-Binding Proteins, Cellular
- Signal Transduction
- Tretinoin/analysis
- Vitamin A/analysis
Collapse
Affiliation(s)
- Y S Kuppumbatti
- Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029-6574, USA
| | | | | | | | | |
Collapse
|
4
|
Hochster H, Speyer JL, Mandeli JP, Runowicz C, Wadler S, Berk G, Wallach R, Holland JF. A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1999; 72:292-7. [PMID: 10053098 DOI: 10.1006/gyno.1998.5261] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
PURPOSE Recombinant human interleukin-6 (rhuIL-6) is a glycosylated cytokine with hematopoietic stimulatory effects. In particular, preclinical studies suggest the agent can stimulate thrombopoiesis, even in conjunction with chemotherapy. We attempted to determine whether higher dose chemotherapy for ovarian cancer was possible given the pharmacologic use of this important growth factor. METHODS We conducted a randomized, double-blind phase II study of IL-6 plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in combination with a standard chemotherapy regimen. Patients with epithelial ovarian cancer, stages Ic to IV, were eligible. All patients were previously untreated with chemotherapy and had Karnofsky performance status >/=60. rhuIL-6 (Escherichia coli, SDZ ILS 969) 1.0 micrograms/kg or placebo was given subcutaneously on days 2-8 every cycle together with G-CSF 5.0 micrograms/kg subcutaneously days 2-15, following administration of paclitaxel 175 mg/m2 as a 3-h infusion and carboplatin given to a desired AUC of 7.5 on day 1 every 21 days. RESULTS Fifty patients were entered in this study, although the study was temporarily suspended by the FDA in midstudy over manufacturing concerns. Therefore, 37 patients were evaluable for efficacy of growth factor; 19 patients received placebo plus G-CSF and 18 rhIL-6 plus G-CSF. There was no difference in prognostic variables between these two groups. Platelet nadirs were lower in the first cycle for the placebo group (P = 0.004, Wilcoxon sum-rank test) but not in other cycles. There was no statistically significant difference in cycle treatment delays, carboplatin dose delivered, number of patients with grade 4 thrombocytopenia, or platelet transfusion. Nonetheless, the trend of the data favored IL-6 in all cases. CONCLUSIONS This study demonstrated a minimal effect (statistically significant in the first cycle only) on thrombopoiesis in women undergoing paclitaxel and carboplatin therapy of ovarian cancer. No clinically significant effect on actual chemotherapy delivery was demonstrated, however. Future studies, if warranted, to ameliorate thrombocytopenia should be carried out with regimens producing even greater thrombocytopenia than the current regimen in the control arm.
Collapse
Affiliation(s)
- H Hochster
- New York University School of Medicine, New York, New York, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Chahinian AP, Mandeli JP, Gluck H, Naim H, Teirstein AS, Holland JF. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J Surg Oncol 1998; 67:104-11. [PMID: 9486781 DOI: 10.1002/(sici)1096-9098(199802)67:2<104::aid-jso6>3.0.co;2-e] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND AND OBJECTIVES Malignant mesothelioma has a poor prognosis and is refractory to many agents. The antitumor effectiveness of cisplatin, paclitaxel, and suramin as single agents and in combination was evaluated in vivo against four lines of human pleural malignant mesothelioma xenografts in athymic nude mice, including one epithelial type and three fibrosarcomatous. METHODS After growth of tumors occurred by day 54 or 55, mice were randomized in groups of four each to receive either cisplatin 4 mg/kg intraperitoneally weekly x5, or paclitaxel (Taxol) 12.5 mg/kg subcutaneously daily 5 days/week for 3 consecutive weeks, or suramin 60 mg/kg intraperitoneally daily x4,versus controls treated with normal saline. RESULTS Cisplatin was very effective against one line and also to a lesser degree against another line. Paclitaxel showed antitumor effects similar to cisplatin, being very effective in one line, and also showed good activity in another line. Suramin was basically inactive in all four lines. Following the results obtained with these single agents, it was decided to evaluate the combination of cisplatin and paclitaxel, which resulted in more pronounced antitumor effect in all four cell lines. CONCLUSIONS These results indicate that the combination of cisplatin and paclitaxel is superior to each agent alone in this model, and that it deserves to be evaluated in patients with malignant mesothelioma.
Collapse
Affiliation(s)
- A P Chahinian
- Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
| | | | | | | | | | | |
Collapse
|
6
|
Kamthan AG, Morris JC, Dalton J, Mandeli JP, Chesser MR, Leben D, Cooperman A, Bruckner HW. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 1997; 15:2920-7. [PMID: 9256136 DOI: 10.1200/jco.1997.15.8.2920] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
PURPOSE To study the outcome achieved with three-drug chemotherapy and split-course external-beam radiotherapy as a treatment for unresectable stage II and III pancreatic carcinoma. PATIENTS AND METHODS Radiotherapy was given in three cycles of 2 Gy/d on days 1 to 5 and 8 to 12 (total dose, 54 Gy) concurrently with fluorouracil (FU) 1,000 mg/m2/d by continuous infusion for 4.5 days, streptozocin (STZ) 300 mg/m2 on days 1, 2, and 3 and cisplatin (P) 100 mg/m2 on day 3 of each every-28-day cycle. Subsequent treatment consisted of leucovorin (LV) 200 mg/m2 and FU 600 to 1,000 mg/m2 every 14 days. RESULTS The median survival time for the 35 patients was 15 months and 26% of patients were alive at 24 months. Fifteen patients (42.8%) had objective responses to therapy. Six (17%) had a complete response (CR). Three of nine patients with partial responses (PRs) achieved a radiographic CR within the next 3 months. Nine patients underwent attempts at surgical resection: five were resected (median survival time, 31 months; range, 12.8 to 44.7+), two had no residual disease found at complete resection, and three others also had a complete resection. Of four others who could not be resected, three underwent intraoperative radiotherapy and one had occult metastatic disease. Of primary tumors, 91% did not produce either back pain or local gastrointestinal complications for 2 years. The rates of severe side effects were stomatitis 15%, anemia 14%, granulocytopenia 6%, and thrombocytopenia 6%. CONCLUSION Palliation and survival compare favorably with other series, including many surgical series. The response findings encourage studies of both unresectable and (as neoadjuvant therapy) resectable tumors.
Collapse
Affiliation(s)
- A G Kamthan
- Section of Hematology/Oncology, West Virginia University Health Sciences Center, Charleston, USA
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Dottino PR, Segna RA, Jennings TS, Mandeli JP, Konsker K, Cohen CJ. Pelvic exenteration in gynecologic oncology: Experience at the Mount Sinai Center, 1975-1992. Mt Sinai J Med 1995; 62:431-5. [PMID: 8692157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Thirty-nine patients underwent pelvic exenteration for gynecologic malignancies at The Mount Sinai Medical Center between 1975 and 1992. Surgical techniques, morbidity, survival, and other variables for patients so treated in two periods, 1975-1984 and 1985-1992, were compared. The primary cancer included squamous cell carcinoma of the cervix, 27; adenocarcinoma of the cervix, 1; squamous cell carcinoma of the vagina, 4; adenocarcinoma of the endometrium, 4; squamous cell carcinoma of the vulva, 2; and adenocarcinoma of the rectum, 1. Median survival was 23.1 months, with a median follow-up of 18 months. Survival was significantly related to status of the lymph nodes (p 0.0004) and surgical margins (p 0.0038). There were two postoperative mortalities, one due to pulmonary embolus and another to myocardial infarction. The ability in the second period analyzed, 1985-1992, to integrate a continent urinary reservoir and supralevator exenteration without colostomy yet not induce increased morbidity or decreased survival, has not been previously reported.
Collapse
Affiliation(s)
- P R Dottino
- Department of Obstetrics, Gynecology and Reproductive Sciences, Mount Sinai Medical Center, New York, NY 10029, USA
| | | | | | | | | | | |
Collapse
|
8
|
Jennings TS, Dottino PR, Mandeli JP, Segna RA, Kelliher K, Cohen CJ. Growth factor expression in normal peritoneum of patients with gynecologic carcinoma. Gynecol Oncol 1994; 55:190-7. [PMID: 7959283 DOI: 10.1006/gyno.1994.1276] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Both epidermal growth factor receptor (EGFR) and HER-2/neu (neu) have been found to be of prognostic importance in epithelial ovarian and endometrial carcinoma, but alterations in proto-oncogene expression of normal tissues of patients with gynecologic malignancies are unknown. Patients (118) undergoing laparotomy for gynecologic indications (78 ovarian cancer, 11 endometrial cancer, 19 benign gynecologic disease, 10 other cancers) had biopsies of normal peritoneum for quantitative assessment of neu and EGFR concentrations. Patients undergoing exploration for gynecologic malignancy were found to have significantly higher median neu expression in the peritoneal biopsies than patients with benign gynecologic disease (P = 0.002). Most patients in this study were found to have ovarian cancer, and median peritoneal neu expression was found to be significantly higher in patients with ovarian cancer versus benign ovarian masses (P = 0.0008) or any benign gynecologic disease (P = 0.004). No significant alteration of unbound EGFR was found in peritoneal biopsies of any of the groups of patients. No associations were found for a history of breast cancer, presence of ascites, or menopausal status with alteration of neu or EGFR expression in normal peritoneum. These findings of altered expression of neu in normal tissues of patients with ovarian cancer are suggestive of the presence of proto-oncogene alterations in loco-regional tissues of the peritoneum, such as might be seen if a paracrine influence existed between tumor and peritoneal cells. Alternatively, the alterations may represent subtle alterations of proto-oncogene expression of germ-line tissues.
Collapse
Affiliation(s)
- T S Jennings
- Department of Obstetrics, Gynecology and Reproductive Sciences, Mount Sinai Hospital, New York, New York 10029
| | | | | | | | | | | |
Collapse
|
9
|
Abstract
PURPOSE This study was undertaken to evaluate the efficacy of secondary surgical cytoreduction in the management of ovarian cancer. PATIENTS AND METHODS The cases of 100 patients with recurrent or progressive epithelial ovarian cancer whose initial treatment had been cytoreduction followed by cytotoxic therapy with a cisplatin-based regimen were reviewed. All 100 patients underwent surgery, after recurrence or progression was documented preoperatively, by gynecologic oncologists at the Mount Sinai Medical Center, New York, NY, between 1980 and 1991 with the intention of performing radical tumor reduction. RESULTS Sixty-one patients had a secondary cytoreduction that left residual disease less than 2 cm in diameter. The median survival, determined from the date of the secondary cytoreduction to the date of death or last follow-up, is 27.1 months in the optimally treated group and 9.0 months for the 39 patients whose surgery was suboptimal (P = .0001). Other variables associated with statistically significant longer survival, and a significantly higher probability of achieving a successful secondary cytoreduction, included age < or = 55 years at the time of secondary cytoreduction, interval from initial diagnosis to secondary cytoreduction of more than 12 months, residual disease at initial staging laparotomy of less than 2 cm, and a complete clinical response to a cisplatin-based front-line regimen. Multivariate analysis confirms the survival benefit provided by a successful secondary cytoreduction when adjusted for the above variables. There was one postoperative mortality. Ten percent of the successfully cytoreduced patients and 18% of the unsuccessfully cytoreduced patients experienced some degree of postoperative morbidity. CONCLUSION These data justify the performance of secondary cytoreductive surgery for patients who develop gross recurrent or progressive ovarian cancer following cisplatin therapy.
Collapse
Affiliation(s)
- R A Segna
- Department of Obstetrics, Gynecology, Mount Sinai Medical Center, New York, NY 10029
| | | | | | | | | |
Collapse
|
10
|
Abstract
Immunoglobulin expression was studied in a series of 345 cases of B-cell lymphoma by immunohistochemical studies and correlated with the histopathologic classification with the use of the Working Formulation. Immunoglobulin expression was present in 254 cases (74%) of B-cell lymphomas (IgM kappa, 122; IgM lambda, 82; light chain only, 40; mu heavy chain only, 10). Immunoglobulin expression occurred with the greatest frequency in lymphomas of small lymphocytic, small cleaved cell, and small noncleaved cell histologic types (93%, 100%, 100%, respectively) and occurred with the least frequency in lymphomas of large cell (cleaved and noncleaved) and immunoblastic histologic types (59% each). Other lymphomas demonstrated intermediate frequencies of immunoglobulin expression. An excess of cases expressing lambda light chain was noted overall (kappa-lambda ratio of 1.3; expected, 2.0) and was particularly evident for intermediate lymphocytic and follicular mixed histologic types (kappa-lambda ratios of 0.8 and 0.9, respectively). Immunoglobulin expression in B-cell lymphomas varies as a function of cellular differentiation as reflected in the histologic type and grade of the Working Formulation. An excess of cases expressing lambda light chain in specific histologic categories suggests the possibility that lymphocytes bearing the lambda light chain rearrangement may be more susceptible to certain types of lymphomatous transformation.
Collapse
MESH Headings
- Antibodies, Monoclonal/immunology
- Antigens, CD19
- Antigens, CD20
- Antigens, Differentiation, B-Lymphocyte/immunology
- Antigens, Differentiation, B-Lymphocyte/metabolism
- Antigens, Differentiation, T-Lymphocyte/immunology
- Antigens, Differentiation, T-Lymphocyte/metabolism
- CD2 Antigens
- Humans
- Immunoglobulin A/immunology
- Immunoglobulin A/metabolism
- Immunoglobulin D/immunology
- Immunoglobulin D/metabolism
- Immunoglobulin G/immunology
- Immunoglobulin G/metabolism
- Immunoglobulin M/immunology
- Immunoglobulin M/metabolism
- Immunoglobulins/metabolism
- Immunohistochemistry/methods
- Lymphoma, B-Cell/classification
- Lymphoma, B-Cell/metabolism
- Lymphoma, B-Cell/pathology
- Receptors, Immunologic/immunology
- Receptors, Immunologic/metabolism
Collapse
Affiliation(s)
- J A Strauchen
- Department of Pathology, Mount Sinai School of Medicine, New York, New York 10029
| | | |
Collapse
|
11
|
Abstract
The growth of MTW9 mammary tumors exhibits different degrees of responsiveness to ovariectomy, ranging from sensitivity to resistance. This range of response is a function of time elapsing from tumor inoculation until performance of ovariectomy provided that prolactin (PRL) level is kept continuously high. In vivo studies showed that the MTW9 tumors developed by chronic administration of spiramide were sensitive to ovariectomy by 60 days, but they became resistant to ovariectomy by 100 days. However, when spiramide treatment was discontinued after tumor appearance, the tumors were still sensitive to ovariectomy by 100 days. Chromatofocusing (CF) profile of cytosolic estrogen receptors (ER) correlated with the responsiveness to ovariectomy. A 2-peak profile for tumors sensitive to ovariectomy, and only a one-peak profile for tumors resistant to ovariectomy, were seen. Although the prolactin level in rats bearing the tumors was higher than in the normal rats, no correlation between the PRL level and the change in CF profile of ER over time was seen. Also, these changes could not be correlated with the tumor size. In vitro studies showed that incubation of cytosolic ER from a sensitive tumor (2 peaks) with PRL led to a CF profile with only one peak, characteristic of a resistant tumor. Leupeptin, molybdate and phenylmethylsulfonylfluoride (PMSF) could not prevent this transition. The effect was not reproduced by incubation with growth hormone or progesterone. Our data suggest that PRL, either directly or through intermediates, may play a role in changing the response to hormonal therapy of the mammary tumor MTW9.
Collapse
Affiliation(s)
- M Platica
- Dept. of Surgery, Mount Sinai School of Medicine, New York, NY
| | | | | | | |
Collapse
|
12
|
DaCosta MC, Luckey MM, Meier DE, Mandeli JP, DeLaney ML, Stritzke PH, Goldsmith SJ. Effect of source strength and attenuation on dual photon absorptiometry. J Nucl Med 1989; 30:1875-80. [PMID: 2809753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
A systematic error in dual photon absorptiometry (DPA) measurements of bone mineral density (BMD) related to source strength has been previously described and attributed to an erroneous algorithm for deadtime correction. Since detected counts (or photon flux) is a product of source strength and attenuation, the effect of various source activities and attenuation depths on BMD calculations were evaluated using a phantom. Ten DPA scans were acquired at two source strengths, 0.3 and 1.0 Ci, and at each of two water depths, 16.4 and 24.5 cm. These activities and depths are within the range encountered clinically. Scans were acquired and processed using a commercially available lumbar spine scanner and software, and were reanalyzed with two upgraded versions of software. Mean BMD obtained with the initial software varied by 2 to 14% with changes in both sources strength and attenuating depth. Software revisions reduced but did not entirely eliminate these differences. The remaining 6% discrepancy is of sufficient magnitude to influence both patient management and research investigations.
Collapse
Affiliation(s)
- M C DaCosta
- Department of Physics-Nuclear Medicine, Mount Sinai Medical Center, New York, New York 10029
| | | | | | | | | | | | | |
Collapse
|
13
|
Luckey MM, Meier DE, Mandeli JP, DaCosta MC, Hubbard ML, Goldsmith SJ. Radial and vertebral bone density in white and black women: evidence for racial differences in premenopausal bone homeostasis. J Clin Endocrinol Metab 1989; 69:762-70. [PMID: 2778034 DOI: 10.1210/jcem-69-4-762] [Citation(s) in RCA: 120] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The reasons for a different incidence of osteoporotic fractures in white and black women are unknown. Previous racial comparisons of bone mass have been limited by racial differences in body weight and socioeconomic, health, and nutritional status. This cross-sectional study examined bone density in 105 black and 114 white healthy nonobese women, 24-65 yr old, using dual photon absorptiometry of the lumbar spine and single photon absorptiometry of the distal radius. Bone density at both sites was higher in blacks at all ages than in whites. When adjusted for age and body mass index, mean bone density was 6.5% higher in blacks at both spine and radius (P less than 0.0001). The cross-sectional rate of decline of vertebral bone density was similar between races; however, radial density increased 3.8%/decade (P = 0.03) in premenopausal blacks under age 46 yr, while it declined 3.2%/decade (P = 0.09) in premenopausal whites. The racial difference in slopes in these premenopausal women is significant (P = 0.002). These findings suggest that attainment of higher peak bone mass and delayed onset of bone loss contribute to the lower incidence of osteoporotic fractures in black women.
Collapse
Affiliation(s)
- M M Luckey
- Department of Obstetrics, Mount Sinai Medical Center, New York, New York 10029
| | | | | | | | | | | |
Collapse
|